APA (7th ed.) Citation

Grimshaw, C. E., Jennings, A., Kamran, R., Ueno, H., Nishigaki, N., Kosaka, T., . . . Takeuchi, K. (2016). Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. PLoS ONE, 11(6), 1. https://doi.org/10.1371/journal.pone.0157509

Chicago Style (17th ed.) Citation

Grimshaw, Charles E., et al. "Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism." PLoS ONE 11, no. 6 (2016): 1. https://doi.org/10.1371/journal.pone.0157509.

MLA (9th ed.) Citation

Grimshaw, Charles E., et al. "Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism." PLoS ONE, vol. 11, no. 6, 2016, p. 1, https://doi.org/10.1371/journal.pone.0157509.